An evaluation of short‐term corticosteroid response in perennial allergic rhinitis using histamine and adenosine monophosphate nasal challenge

Publisher Website
Google Scholar
Abstract
Aims  To evaluate the role of AMP nasal challenge as a measure of short‐term treatment response in patients receiving intranasal corticosteroids. Adenosine monophosphate (AMP) challenge has been shown to be a good inflammatory surrogate in the lower airways, but it has not been properly evaluated as a nasal challenge test.Methods  Fourteen patients with perennial allergic rhinitis (PAR) were randomized to receive 2 weeks treatment with placebo (PL) or 200 µg intranasal mometasone furoate (MF) once daily in a randomized single‐blind crossover study. AMP (25–800 mg ml−1) and histamine (0.25–8 mg ml−1) nasal challenge testing were performed after each treatment period with 30% decrease in minimal cross‐sectional area (MCA). Domiciliary symptom data were collected.Results  There was a significant (P < 0.05) improvement in PC30 MCA and nasal volume with AMP but not with histamine comparing MF vs PL. This amounted to a 2.8 (95% CI 1.5, 4.0) and 0.7 (95% CI −0.5, 1.9) doubling‐dose change for AMP and histamine challenges, respectively. There were significant (P < 0.05) improvements in nasal symptoms and quality of life.Conclusions  AMP nasal challenge using acoustic rhinometry may be a useful test to assess short‐term treatment response in patient with PAR.

This publication has 25 references indexed in Scilit: